CalciMedica (NASDAQ:CALC) Shares Scheduled to Reverse Split on Monday, August 31st

CalciMedica Inc. (NASDAQ:CALC)’s stock is scheduled to reverse split on Monday, August 31st. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 30th.

CalciMedica Stock Performance

Shares of CalciMedica stock traded down $0.12 on Thursday, reaching $0.47. The stock had a trading volume of 1,490,454 shares, compared to its average volume of 335,053. The business’s 50-day moving average price is $0.75 and its two-hundred day moving average price is $0.70. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. CalciMedica has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The stock has a market cap of $16.05 million, a P/E ratio of -0.35 and a beta of 0.91.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.17). On average, sell-side analysts forecast that CalciMedica will post -1.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CALC shares. Guggenheim began coverage on CalciMedica in a research report on Thursday, August 20th. They issued a “buy” rating on the stock. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Wall Street Zen raised CalciMedica to a “sell” rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings downgraded CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CalciMedica has a consensus rating of “Hold” and a consensus target price of $10.00.

Insider Activity

In other CalciMedica news, Director Fred A. Middleton acquired 248,972 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was bought at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the purchase, the director owned 1,063,272 shares in the company, valued at $850,617.60. This represents a 30.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. boosted its stake in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares in the last quarter. Cetera Investment Advisers lifted its holdings in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of CalciMedica in the fourth quarter valued at approximately $302,000. Renaissance Technologies LLC boosted its stake in CalciMedica by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after purchasing an additional 18,300 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in CalciMedica during the 4th quarter worth about $127,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.